Ikena Oncology, Inc.
IKNA
$1.14
-$0.01-0.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -61.48% | -67.91% | -53.47% | -33.52% | -37.98% |
| Gross Profit | 61.48% | 66.36% | 49.38% | 22.59% | 5.80% |
| SG&A Expenses | -5.92% | -8.42% | -20.83% | -0.26% | 13.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.18% | -46.05% | -43.95% | -26.12% | -24.89% |
| Operating Income | 40.18% | 44.43% | 40.55% | 18.12% | -0.83% |
| Income Before Tax | 46.70% | 53.84% | 41.05% | 20.14% | -13.36% |
| Income Tax Expenses | 3.70% | 132.72% | -- | -- | -- |
| Earnings from Continuing Operations | 46.62% | 53.18% | 40.99% | 19.78% | -13.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.62% | 53.18% | 40.99% | 19.78% | -13.55% |
| EBIT | 40.18% | 44.43% | 40.55% | 18.12% | -0.83% |
| EBITDA | 39.89% | 44.05% | 40.27% | 17.54% | -0.92% |
| EPS Basic | 46.62% | 53.55% | 46.88% | 34.69% | 14.69% |
| Normalized Basic EPS | 47.12% | 55.91% | 51.14% | 38.21% | 28.48% |
| EPS Diluted | 46.62% | 53.55% | 46.88% | 34.69% | 14.69% |
| Normalized Diluted EPS | 47.12% | 55.91% | 51.14% | 38.21% | 28.48% |
| Average Basic Shares Outstanding | 0.00% | 0.80% | 11.10% | 22.82% | 33.10% |
| Average Diluted Shares Outstanding | 0.00% | 0.80% | 11.10% | 22.82% | 33.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |